Altria's Fourth-Quarter and Full-Year 2025 Earnings Conference Call January 29, 2026 1 | ALCS | Q4 2025 | 1.29.26 | For Investor Purposes ONLY Safe Harbor Statement Statements, including earnings guidance, in this presentation that are not reported financial results or other historical information are "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current plans, estimates and expectations, and are not guarante ...

Core Viewpoint - Tobacco company Altria has forecasted full-year profit that exceeds analysts' estimates, driven by price increases for its cigarette and oral tobacco products [1] Group 1 - Altria's profit forecast indicates a positive outlook for the company, suggesting strong demand and pricing power in its product categories [1] - The price hikes for both cigarette and oral tobacco products are key factors contributing to the improved profit outlook [1]

Altria Is Losing Ground in the Smokeless Tobacco Race. The Stock Is Falling. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Altria Is Losing Ground in the Smokeless Tobacco Race. The Stock Falls After Earnings.By [Nate Wolf]ShareResize---R ...

The maker of Marlboro cigarettes reports weaker-than-expected quarterly earnings. ...

Core Insights - Altria reported a decline in fourth-quarter profit due to a decrease in cigarette shipment volume, negatively impacting its smokeable product business [1] Financial Performance - The company's fourth-quarter profit was lower compared to previous periods, primarily driven by reduced cigarette shipments [1] Market Trends - The decline in cigarette shipment volume indicates a broader trend affecting the smokeable product market, suggesting potential challenges for the industry [1]

Altria Group, Inc. (NYSE:MO) is one of the 11 Most Profitable Cheap Stocks to Invest In Now. On January 26, UBS increased its price target on Altria Group, Inc. (NYSE:MO) from $63 to $67 and maintained its Buy rating on the stock. The firm noted that risks facing the company, including worries around combustible volume mix, duty drawback benefits, and lower nicotine pouch volumes, are manageable. UBS also noted that while progress in smoke-free products is slow, Altria Group, Inc. (NYSE:MO) is still well ...

Core Insights - Altria Group, Inc. is expected to report its fourth-quarter 2025 earnings on January 29, with revenues projected at $5 billion, reflecting a 2% decline year-over-year, while earnings per share (EPS) is estimated at $1.31, indicating a 1.6% growth from the previous year [1][9] Earnings Performance - Altria has a trailing four-quarter average earnings surprise of 3.1%, with the last quarter's earnings surpassing the Zacks Consensus Estimate by 0.7% [2] - The company currently has an Earnings ESP of +1.54% and a Zacks Rank of 3 (Hold), suggesting a favorable outlook for an earnings beat [4][3] Factors Influencing Q4 Earnings - The fourth-quarter performance is likely influenced by disciplined pricing and effective cost control, despite pressure on domestic cigarette shipment volumes due to inflation [5] - Altria has maintained steady profitability through solid revenue management and disciplined cost control, with pricing gains across core smokeable brands cushioning operating income [6] Oral Tobacco Business - A significant contributor to Altria's earnings is its oral tobacco business, particularly nicotine pouches, which have aided segment profitability despite competitive pressures [7] Stock Performance - Over the past three months, Altria's stock has gained 0.6%, underperforming the Zacks Tobacco industry's 12.1% increase and the Consumer Staples sector's 3.7% growth [8] - Compared to peers, Altria's stock performance has lagged, with competitors like Philip Morris and British American Tobacco showing higher gains [8] Valuation - Altria's shares are trading at a forward 12-month price-to-earnings ratio of 11.39, below the industry average of 15.48, indicating compelling value for investors [10] - The valuation gap is notable when compared to key competitors, which have significantly higher P/E ratios [11] Investment Outlook - Altria demonstrates resilience through effective pricing strategies and cost management, offsetting volume pressures in its core cigarette business [12] - The expanding smoke-free portfolio, particularly nicotine pouches, is a key driver for margin support and earnings stability, making Altria an appealing defensive consumer staples stock [12]

Core Viewpoint - Cabbacis is positioned to capitalize on the growing demand for risk-reduction tobacco products, particularly through its iBlend™ brand, which features very-low-nicotine cigarettes and aims to address public health concerns related to tobacco use [2][4][16]. Company Milestones and Achievements - 2025 was a transformative year for Cabbacis, marked by positive clinical trial results for iBlend™ very-low-nicotine cigarettes, advancing the company's commercialization pathway and first-to-market advantage [2][6]. - The company has made significant progress in developing its products and has a clean balance sheet with no debt, targeting a $7.5 million capital raise to support operations for the next two years [12][13]. Product Strategy and Market Opportunity - iBlend™ cigarettes contain approximately 95% less nicotine than leading brands, addressing the need for alternative products to help smokers reduce nicotine dependence and quit [3][7]. - The FDA's proposed rule to limit nicotine levels in cigarettes could create a favorable market environment for iBlend™, potentially transforming the global tobacco market [8]. Clinical Validation and Intellectual Property - A pilot clinical trial showed that iBlend™ products received strong satisfaction scores and significantly reduced cravings for usual brand cigarettes, indicating consumer acceptance [10][17]. - Cabbacis holds a robust intellectual property portfolio with 36 worldwide patents, including 8 U.S. patents, covering innovative tobacco and hemp product combinations [11][17]. Regulatory Pathway and Future Plans - The company plans to file a Premarket Tobacco Product Application (PMTA) for iBlend™ around mid-2026, with expectations for a review process of approximately one year [14]. - Cabbacis aims to initiate international marketing efforts in select markets with lower regulatory barriers, allowing for early revenue generation and brand validation ahead of U.S. market entry [14].

Core Insights - The research study commissioned by AIR Limited demonstrates that the use of AIR's OOKA charcoal-free waterpipe and electronic vaping products significantly reduces secondhand toxicant exposure compared to traditional smoking methods [1][2] Group 1: Study Findings - The study found that the use of AIR's OOKA and electronic vaping products resulted in significantly lower levels of harmful chemicals and pollutants in indoor air compared to conventional waterpipes and combustible cigarettes [1] - In one-occupant scenarios, the study observed nearly complete elimination of carbon monoxide (CO), formaldehyde, benzene, and NNK (a tobacco-specific carcinogen) when using AIR's OOKA [1] - Particulate matter levels (PM10 and PM2.5) were approximately 40% lower during the use of AIR's OOKA compared to conventional waterpipe use [1] Group 2: Multi-Occupant Scenarios - In scenarios with ten occupants, increases in volatile organic compounds and polycyclic aromatic hydrocarbons were primarily observed during cigarette smoking, while negligible levels were noted during the use of other products [1] Group 3: Company Background - AIR Limited, founded in 1999 and headquartered in Dubai, operates in over 90 markets globally and includes brands such as Al Fakher and Hookah.com in its portfolio [2] - The company is positioned as a leader in social inhalation innovation, focusing on minimizing harm while maximizing enjoyment through advanced technology [2] Group 4: Business Combination - AIR announced a definitive business combination agreement with Cantor Equity Partners III, which is expected to result in AIR Global Limited becoming publicly listed on Nasdaq under the ticker symbol "AIIR" in the first half of 2026 [1][2]

Virginia-based Altria Group, Inc. (MO) manufactures and sells smokeable and oral tobacco products. Valued at $104.1 billion by market cap, the company offers cigarettes primarily under the Marlboro brand, large cigars and pipe tobacco under the Black & Mild brand, moist smokeless tobacco and snus products under the Copenhagen, Skoal, Red Seal, and Husky brands, and more. Shares of this leading tobacco company have outperformed the broader market over the past year. MO has gained 19% over this time frame, ...